Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 17, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.81 million shares for a total of 47.19 million yuan, representing 1.532% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.62 million yuan, accounting for 1.083% of its total share capital [2]. - Sinopec Limited (00386) repurchased 3.79 million shares for 16.73 million yuan, which is 0.120% of its total share capital [2]. Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 1.71 million shares for 13.67 million yuan, representing 2.608% of its total share capital [2]. - Linklogis Technology (09959) repurchased 2.65 million shares for 7.40 million yuan, accounting for 4.885% of its total share capital [2]. - Jitu Express (01519) repurchased 640,000 shares for 6.25 million yuan, which is 0.041% of its total share capital [2]. Group 3: Additional Companies - Mengniu Dairy (02319) repurchased 200,000 shares for 2.98 million yuan, representing 0.660% of its total share capital [2]. - Kangning Jereh Pharmaceutical (09966) repurchased 350,000 shares for 3.42 million yuan, accounting for 0.211% of its total share capital [3]. - Huajian Medical (01931) repurchased 593,000 shares for 3.64 million yuan, which is 0.660% of its total share capital [3].

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 60,000 shares at a price range of HKD 1.80 to HKD 1.81, totaling HKD 10.85 million, on November 17, 2025 [1] Company Summary - As of November 17, 2025, Hema Medical's stock closed at HKD 1.80, down 1.64%, with a trading volume of 207,800 shares and a turnover of HKD 374,300 [1] - The company has a market capitalization of HKD 2.268 billion and ranks 16th in the medical services sector [1] Financial Metrics - Return on Equity (ROE): -6.36%, compared to the industry average of 0.02%, ranking 39th out of 60 [1] - Market Capitalization: HKD 2.268 billion, while the industry average is HKD 8.332 billion, ranking 16th out of 60 [1] - Revenue: HKD 1.935 billion, with the industry average at HKD 3.832 billion, ranking 15th out of 60 [1] - Net Profit Margin: 5.95%, compared to an industry average of -843.36%, ranking 25th out of 60 [1] - Gross Profit Margin: 31.12%, while the industry average is 39.76%, ranking 28th out of 60 [1] - Debt Ratio: 29.8%, compared to the industry average of 74.15%, ranking 21st out of 60 [1]

Core Viewpoint - The company, 希玛医疗 (03309), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 60,000 shares at a total cost of HKD 10.85 million [1] - The buyback price per share ranges from HKD 1.80 to HKD 1.81 [1] - The buyback is scheduled for November 17, 2025 [1]

Summary of Key Points - Company repurchased shares on November 17, spending HKD 108,000 to buy back 60,000 shares [1] - Prior to this, on November 14, the company spent HKD 369,000 to repurchase 200,000 shares [1]

Group 1 - The company, Hema Medical (03309), announced a share buyback plan on November 17, 2025, involving an expenditure of HKD 10.85 million to repurchase 60,000 shares [1] - The repurchase price per share is set between HKD 1.80 and HKD 1.81 [1]

公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年11月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Core Viewpoint - Multiple companies conducted share buybacks on November 14, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.70 million shares for a total of 46.13 million yuan, representing 1.412% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3.00 million shares for 42.58 million yuan, accounting for 0.979% of its total share capital [2]. - Sinopec Limited (00386) repurchased 6.74 million shares for 29.82 million yuan, which is 0.120% of its total share capital [2]. - AAC Technologies (02018) repurchased 300,000 shares for 11.97 million yuan, representing 0.212% of its total share capital [2]. - Yimeng Sunshine (N23020) repurchased 604,000 shares for 9.97 million yuan, accounting for 1.732% of its total share capital [2]. Group 2: Other Notable Buybacks - Kweichow Moutai (09987) repurchased 17,400 shares for 6.27 million yuan, which is 3.190% of its total share capital [2]. - Antong Oilfield Services (03337) repurchased 6.01 million shares for 5.99 million yuan, representing 1.660% of its total share capital [2]. - MGM China (02282) repurchased 338,700 shares for 5.45 million yuan, accounting for 0.763% of its total share capital [2]. - China Feihe (06186) has a cumulative buyback of 12.8 million shares for the year, which is 1.412% of its total share capital [2].

Summary of Key Points Core Viewpoint - On November 14, 2023, the company Xima Medical (03309.HK) announced a share buyback, spending HKD 369,000 to repurchase 200,000 shares [1] Group 1 - The total expenditure for the share buyback was HKD 369,000 [1] - The number of shares repurchased in this transaction was 200,000 [1]

希玛医疗(03309)发布公告，于2025年11月14日，该公司斥资36.87万港元回购20万股股份，每股回购价 格为1.83-1.85港元。 ...

智通财经APP讯，希玛医疗(03309)发布公告，于2025年11月14日，该公司斥资36.87万港元回购20万股 股份，每股回购价格为1.83-1.85港元。 ...